CRA31 RIFAMPICIN- INDUCED ACUTE PANCREATITIS: A CASE REPORT AND REVIEW OF LITERATURE

Wan Yi Leong, Suat Yee Lim, Rozanah Abd Rahman
Hospital Sultanah Aminah Johor Bahru, Johor, Malaysia

Drug-induced acute pancreatitis is a rare but recognized adverse effect of various medications, including anti-tuberculosis drugs. Rifampicin, a cornerstone in tuberculosis treatment, has been reported as one of the causative drugs. We present a case of an elderly woman diagnosed with smear-positive pulmonary tuberculosis who developed jaundice and abdominal pain shortly after initiating first line anti-tuberculosis treatment with rifampicin. Her peak serum amylase was significantly elevated (1292 U/L), along with hyperbilirubinemia and transaminitis. Her clinical course, laboratory findings, and resolution upon discontinuation of rifampicin highlight the importance of early recognition and management of this potentially serious adverse event. A high index of suspicion should be maintained for drug-induced acute pancreatitis if a patient presents with clinical symptoms such as abdominal pain, jaundice, and elevated serum amylase. In summary, while drug-induced acute pancreatitis from anti-tuberculosis medications is uncommon, vigilance and prompt management are essential for successful treatment outcomes. Rifampicin should be permanently avoided in patients who develop pancreatitis related to its use. A review of the literature regarding rifampicin-induced pancreatitis is also provided to enhance awareness and understanding of this uncommon complication.